Factors Associated with Severe COVID-19 Among Patients with Rheumatoid Arthritis: A Large, Nationwide Electronic Health Record Cohort Study in the United States-Reference-Cited by-同舟云学术

Factors Associated with Severe COVID-19 Among Patients with Rheumatoid Arthritis: A Large, Nationwide Electronic Health Record Cohort Study in the United States

Published:2023-06-20 Issue:9 Volume:40 Page:3723-3738
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Ye Yizhou^ORCID,Yue Xiaomeng,Krueger Whitney S.,Wegrzyn Lani R.,Maniccia Anna W.,Winthrop Kevin L.,Kim Seoyoung C.

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02533-x.pdf

Reference29 articles.

1. Johns Hopkins University of Medicine Coronavirus Resource Center. Mortality analyses; 2021. https://coronavirus.jhu.edu/map.html.

2. Centers for Disease Control and Prevention. CDC updates, expands list of people at risk of severe COVID-19 illness; 2020. https://www.cdc.gov/media/releases/2020/p0625-update-expands-covid-19.html.

3. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.

4. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19—Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):545–50.

5. Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol. 2021;17(2):71–2.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials;Rheumatology and Therapy;2024-04-29

2. Systematic review and meta-analysis of anti-CD20 treatments in patients with COVID-19: an assessment of severe illness and mortality outcomes;Inflammopharmacology;2023-10-07